Unknown

Dataset Information

0

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.


ABSTRACT: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL).Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ?2.3 and ?5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively.A total of 1236 participants (O/O, n?=?607; P/O, n?=?629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p?

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC4959035 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.

Lipton Richard B RB   Rosen Noah L NL   Ailani Jessica J   DeGryse Ronald E RE   Gillard Patrick J PJ   Varon Sepideh F SF  

Cephalalgia : an international journal of headache 20160610 9


<h4>Background</h4>Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL).<h4>Methods</h4>Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) g  ...[more]

Similar Datasets

| S-EPMC7648806 | biostudies-literature
| S-EPMC5539058 | biostudies-literature
| S-EPMC4552933 | biostudies-literature
| S-EPMC4033567 | biostudies-literature
| S-EPMC4233954 | biostudies-literature
| S-EPMC5915521 | biostudies-other
| S-EPMC8173963 | biostudies-literature
| S-EPMC9868805 | biostudies-literature
| PRJEB20258 | ENA
| S-EPMC7455346 | biostudies-literature